These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34754429)

  • 1. Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease.
    El-Damanawi R; Lee M; Harris T; Cowley LB; Scholtes I; Bond S; Sandford RN; Wilkinson IB; Casteleijn NF; Hogan MC; Karet Frankl FE; Hiemstra TF
    Clin Kidney J; 2021 Nov; 14(11):2338-2348. PubMed ID: 34754429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autosomal dominant polycystic kidney disease: possibly the least silent cause of chronic kidney disease.
    Torra R; Pérez-Gómez MV; Furlano M
    Clin Kidney J; 2021 Nov; 14(11):2281-2284. PubMed ID: 34754424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.
    El-Damanawi R; Lee M; Harris T; Mader LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Burrows A; Woznowski P; Ben-Shlomo Y; Karet Frankl FE; Hiemstra TF
    BMJ Open; 2018 May; 8(5):e022859. PubMed ID: 29743334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Yarlas A; Bjorner JB; Krasa H
    Kidney Med; 2024 Jan; 6(1):100755. PubMed ID: 38192435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Cole JC; Atkinson MJ; Krasa HB; Davison SN; Perrone RD
    Clin J Am Soc Nephrol; 2023 Feb; 18(2):213-222. PubMed ID: 36754008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
    Oberdhan D; Cole JC; Krasa HB; Cheng R; Czerwiec FS; Hays RD; Chapman AB; Perrone RD
    Am J Kidney Dis; 2018 Feb; 71(2):225-235. PubMed ID: 29150246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
    D'Agnolo HMA; Casteleijn NF; Gevers TJG; de Fijter H; van Gastel MDA; Messchendorp AL; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JFM; Zietse R; Gansevoort RT; Drenth JPH
    Am J Nephrol; 2017; 46(3):239-248. PubMed ID: 28881341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease.
    Simms RJ; Thong KM; Dworschak GC; Ong AC
    Nephrol Dial Transplant; 2016 Jul; 31(7):1130-40. PubMed ID: 26268712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.
    Cho Y; Rangan G; Logeman C; Ryu H; Sautenet B; Perrone RD; Nadeau-Fredette AC; Mustafa RA; Htay H; Chonchol M; Harris T; Gutman T; Craig JC; Ong ACM; Chapman A; Ahn C; Coolican H; Kao JT; Gansevoort RT; Torres V; Pei Y; Johnson DW; Viecelli AK; Teixeira-Pinto A; Howell M; Ju A; Manera KE; Tong A
    Am J Kidney Dis; 2020 Sep; 76(3):361-373. PubMed ID: 32359822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
    Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
    Xue C; Zhou CC; Wu M; Mei CL
    Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.
    Sautenet B; Cho Y; Gutman T; Rangan G; Ong A; Chapman AB; Ahn C; Coolican H; Tze-Wah Kao J; Fowler K; Gansevoort RT; Geneste C; Perrone RD; Harris T; Torres VE; Pei Y; Craig JC; Tong A;
    Am J Kidney Dis; 2020 Aug; 76(2):213-223. PubMed ID: 32171640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review.
    Natale P; Hannan E; Sautenet B; Ju A; Perrone RD; Burnette E; Casteleijn N; Chapman A; Eastty S; Gansevoort R; Hogan M; Horie S; Knebelmann B; Lee R; Mustafa RA; Sandford R; Baumgart A; Tong A; Strippoli GFM; Craig JC; Rangan GK; Cho Y
    PLoS One; 2021; 16(5):e0252479. PubMed ID: 34043715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.